Experts say numbers of rare blood clots remain low and benefits of vaccine far outweigh risks of Covid-19 infection
Further cases of a rare blood clotting syndrome and seven deaths have been reported among recipients of the Oxford/AstraZeneca jab in the UK, although experts say the numbers remain low and the benefits of the vaccine far outweigh any risks.
The Medicines and Healthcare products Regulatory Agency (MHRA), runs a “yellow card” scheme to pick up suspected side-effects or other concerns for medicines and medical devices.
